These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
509 related articles for article (PubMed ID: 38558810)
1. GD2-targeting therapy: a comparative analysis of approaches and promising directions. Philippova J; Shevchenko J; Sennikov S Front Immunol; 2024; 15():1371345. PubMed ID: 38558810 [TBL] [Abstract][Full Text] [Related]
2. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. Nazha B; Inal C; Owonikoko TK Front Oncol; 2020; 10():1000. PubMed ID: 32733795 [TBL] [Abstract][Full Text] [Related]
3. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape. Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337 [TBL] [Abstract][Full Text] [Related]
4. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Heczey A; Liu D; Tian G; Courtney AN; Wei J; Marinova E; Gao X; Guo L; Yvon E; Hicks J; Liu H; Dotti G; Metelitsa LS Blood; 2014 Oct; 124(18):2824-33. PubMed ID: 25049283 [TBL] [Abstract][Full Text] [Related]
5. Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer. Reppel L; Tsahouridis O; Akulian J; Davis IJ; Lee H; Fucà G; Weiss J; Dotti G; Pecot CV; Savoldo B J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022195 [TBL] [Abstract][Full Text] [Related]
6. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667 [TBL] [Abstract][Full Text] [Related]
7. Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma. Wu H; Zhang G; Liu Z; Liu W; Wang X; Zhao Y Cytotherapy; 2024 Nov; 26(11):1308-1319. PubMed ID: 38904586 [TBL] [Abstract][Full Text] [Related]
8. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15. Chen Y; Sun C; Landoni E; Metelitsa L; Dotti G; Savoldo B Clin Cancer Res; 2019 May; 25(9):2915-2924. PubMed ID: 30617136 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma. Tomida A; Yagyu S; Nakamura K; Kubo H; Yamashima K; Nakazawa Y; Hosoi H; Iehara T Cancer Sci; 2021 Oct; 112(10):4026-4036. PubMed ID: 34382720 [TBL] [Abstract][Full Text] [Related]
10. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma. Seidel D; Shibina A; Siebert N; Wels WS; Reynolds CP; Huebener N; Lode HN Cancer Immunol Immunother; 2015 May; 64(5):621-34. PubMed ID: 25711293 [TBL] [Abstract][Full Text] [Related]
11. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model. Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536 [TBL] [Abstract][Full Text] [Related]
13. Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas. Zuo P; Li Y; He C; Wang T; Zheng X; Liu H; Wu Z; Zhang J; Liao X; Zhang L Front Immunol; 2023; 14():1145706. PubMed ID: 37251413 [TBL] [Abstract][Full Text] [Related]
14. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma. Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106 [TBL] [Abstract][Full Text] [Related]
15. Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma. Chan GC; Chan CM Biomolecules; 2022 Feb; 12(3):. PubMed ID: 35327550 [TBL] [Abstract][Full Text] [Related]